Subclinical rejection in tacrolimus-treated renal transplant recipients

Gloor, James M., Cohen, Ari J., Lager, Donna J., Grande, Joseph P., Fidler, Mary E., Velosa, Jorge A., Larson, Timothy S., Schwab, Thomas R., Griffin, Matthew D., Prieto, Mikel, Nyberg, Scott L., Sterioff, Sylvester, Kremers, Walter K. and Stegall, Mark D. (2002) Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation, 73 12: 1965-1968. doi:10.1097/00007890-200206270-00023

Author Gloor, James M.
Cohen, Ari J.
Lager, Donna J.
Grande, Joseph P.
Fidler, Mary E.
Velosa, Jorge A.
Larson, Timothy S.
Schwab, Thomas R.
Griffin, Matthew D.
Prieto, Mikel
Nyberg, Scott L.
Sterioff, Sylvester
Kremers, Walter K.
Stegall, Mark D.
Title Subclinical rejection in tacrolimus-treated renal transplant recipients
Journal name Transplantation   Check publisher's open access policy
ISSN 0041-1337
Publication date 2002-06
Sub-type Article (original research)
DOI 10.1097/00007890-200206270-00023
Volume 73
Issue 12
Start page 1965
End page 1968
Total pages 4
Place of publication Philadelphia, PA, United States
Publisher Lippincott Williams & Wilkins
Language eng
Formatted abstract
Background. Subclinical rejection, defined as histologic acute rejection in the absence of graft dysfunction, has been suggested as a cause of chronic allograft rejection. In cyclosporine-treated patients, the incidence of subclinical rejection 3 months after transplant is reported to be approximately 30%. The intent of our study was to determine the incidence of subclinical rejection in tacrolimus-treated renal allograft recipients.

Methods. We prospectively studied the incidence of subclinical rejection on surveillance biopsies performed 3 months after transplantation in 114 patients transplanted between September 1, 1998 and November 30, 2000. All patients received tacrolimus, mycophenolate mofetil, and prednisone, and 56% received antibody induction.

Results. Subclinical rejection was detected in 2.6% of patients (3/114, 95% confidence interval 0.5-7.5%). Borderline changes were detected in 11% (12/114). Subclinical rejections were treated with bolus methylprednisolone.

Conclusions. The incidence of subclinical rejection early after kidney transplantation is extremely low in tacrolimus-treated patients in whom early rejections are aggressively treated, suggesting that surveillance biopsies may not be necessary with this regimen.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 66 times in Thomson Reuters Web of Science Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 14 Mar 2011, 08:51:37 EST